Carolina Fazio

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

Luana Calabrò, Aldo Morra, Ester Fonsatti et al. · The Lancet Respiratory Medicine · 2015 · 203 citations

Surgical Oncology, Oncology, Cancer Management +7

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

Riccardo Danielli, Roberto Patuzzo, Anna Maria Di Giacomo et al. · Cancer Immunology Immunotherapy · 2015 · 173 citations · Full text

Medicine, Melanoma, Immunology +8

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

Anna Maria Di Giacomo, Luana Calabrò, Riccardo Danielli et al. · Cancer Immunology Immunotherapy · 2013 · 134 citations · Full text

Expanded Access Programme, Oncology, Skin Cancer +9

Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

Anna Maria Di Giacomo, Alessia Covre, Francesca Finotello et al. · Clinical Cancer Research · 2019 · 77 citations · Full text

Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models

Alessia Covre, Sandra Coral, Hugues J. M. Nicolay et al. · OncoImmunology · 2015 · 69 citations · Full text